O-Glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Shrikhande, Gautam V ^a,b   Scali, Salvatore T ^a,c   da Silva, Cleide G ^a   Damrauer, Scott M ^a   Csizmadia, Eva ^a   Putheti, Prabhakar ^a   Matthey, Michaela ^a   Arjoon, Roy ^a   Patel, Rakesh ^a   Siracuse, Jeffrey J ^a   Maccariello, Elizabeth R ^a,d   Andersen, Nicholas D ^a,e   Monahan, Thomas ^a   Peterson, Clayton ^a   Essayagh, Sanah ^a   Studer, Peter ^a   Guedes, Renata Padilha ^a   Kocher, Olivier ^a   Usheva, Anny ^a   Veves, Aristidis ^a   Kaczmarek, Elzbieta ^a   Ferran, Christiane ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN E; GLUCOSAMINE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEASOME; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CYSTEINE PROTEINASE; IMMUNOGLOBULIN RECEPTOR; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, MOUSE; UBIQUITIN;

ACETYLATION; ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UBIQUITINATION; UPREGULATION; VASCULAR ENDOTHELIUM; VEIN GRAFT; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; TRANSGENIC MOUSE;

MUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYSTEINE ENDOPEPTIDASES; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; UBIQUITIN;

EID: 78650142697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014240     Document Type: Article

References (57)

1. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, et al. (2004) Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109: 2617-2625.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
3. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, et al. (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42: 80-89.
4. Alpert E, Gruzman A, Riahi Y, Blejter R, Aharoni P, et al. (2005) Delayed autoregulation of glucose transport in vascular endothelial cells. Diabetologia 48: 752-755.
5. Nishikawa T, Edelstein D, Du XL, Yamagishi D, Matsumura T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
6. Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, et al. (2004) Selective inhibition of protein kinase C b2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 110: 91-96.
7. Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93: 1159-1169.
8. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
9. Jackson SP, Tjian R (1988) O-glycosylation of eukaryotic transcription factors: Implications for mechanisms of transcriptional regulation. Cell 55: 125-133.
10. Wells L, Vosseller K, Hart GW (2001) Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291: 2376-2378.
11. Zachara NE, Hart GW (2004) O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta 1673: 13-28.
12. Vosseller K, Wells L, Lane MD, Hart GW (2002) Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 99: 5313- 5318.
13. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, et al. (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348.
14. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, et al. (2002) Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106: 466-472.
15. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI (2007) Glycosylation Mediates Up-regulation of a Potent Antiangiogenic and Proatherogenic Protein, Thrombospondin-1, by Glucose in Vascular Smooth Muscle Cells. J Biol Chem 282: 5704-5714.
16. Idel S, Dansky HM, Breslow JL (2003) A20, a regulator of NFkB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci U S A 100: 14235-14240.
17. Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL (2007) The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes. Proc Natl Acad Sci U S A 104: 18601-18606.
18. Patel VI, Daniel S, Longo CR, Shrikhande GV, Scali ST, et al. (2006) A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. Faseb J 20: 1418-1430.
19. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, et al. (1996) A20 blocks endothelial cell activation through a NF-kB-dependent mechanism. J Biol Chem 271: 18068-18073.
20. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, et al. (2003) A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 108: 1113-1118.
21. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, et al. (2004) A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 104: 2376-2384.
22. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, et al. (2004) Deubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694-699.
23. Shembade N, Ma A, Harhaj EW (2010) Inhibition of NF-{kappa}B Signaling by A20 Through Disruption of Ubiquitin Enzyme Complexes. Science 327: 1135-1139.
24. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW (2009) The ubiquitinediting enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. Embo J 28: 513-522.
25. Opipari AJ, Boguski MS, Dixit VM (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265: 14705-14708.
26. Medzihradszky KF (2008) Characterization of site-specific N-glycosylation. Methods Mol Biol 446: 293-316.
27. Gupta R, Brunak S (2002) Prediction of glycosylation across the human proteome and the correlation to protein function. Pacific Symposium on Biocomputing 7: 310-322.
28. Monsigny M, Roche AC, Sene C, Maget-Dana R, Delmotte F (1980) Sugarlectin interactions: how does wheat-germ agglutinin bind sialoglycoconjugates? Eur J Biochem 104: 147-153.
29. Zachara NE, Cheung WD, Hart GW (2004) Nucleocytoplasmic glycosylation, O-GlcNAc: identification and site mapping. Methods Mol Biol 284: 175-194.
30. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, et al. (2007) IKK{beta} phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF{kappa}B pathway. Mol Cell Biol.
31. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108: 1070-1077.
32. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 97: 889-901.
33. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr., et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031.
34. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F (2000) Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med 248: 67-76.
35. Foss MC, Foss NT, Paccola GM, Silva CL (1992) Serum levels of tumor necrosis factor in insulin-dependent diabetic patients. Braz J Med Biol Res 25: 239-242.
36. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
37. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358: 2630-2633.
38. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, et al. (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363: 233-244.
39. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM (1992) The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating NF-kB. J BiolChem 267: 24157-24160.
40. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, et al. (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97: 12222-12226.
41. Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068.
42. Guinez C, Mir AM, Dehennaut V, Cacan R, Harduin-Lepers A, et al. (2008) Protein ubiquitination is modulated by O-GlcNAc glycosylation. Faseb J.
43. Zachara NE, Hart GW (2004) O-GlcNAc modification: a nutritional sensor that modulates proteasome function. Trends Cell Biol 14: 218-221.
44. Han I, Kudlow JE (1997) Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 17: 2550-2558.
45. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, et al. (2003) O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115: 715-725.
46. Su K, Roos MD, Yang X, Han I, Paterson AJ, et al. (1999) An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J Biol Chem 274: 15194-15202.
47. Butkinaree C, Park K, Hart GW (2009) O-linked beta-N-acetylglucosamine (OGlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta 1800: 96-106.
48. Brownlee M (1995) Advanced protein glycosylation in diabetes. Ann Rev Med 46: 223-234.
49. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, et al. (2007) Tag Polymorphisms at the A20 (TNFAIP3) Locus Are Associated With Lower Gene Expression and Increased Risk of Coronary Artery Disease in Type 2 Diabetes. Diabetes 56: 499-505.
50. James LR, Tang D, Ingram A, Ly H, Thai K, et al. (2002) Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes 51: 1146-1156.
51. Bach FH, Hancock WW, Ferran C (1997) Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol Today 18: 483-486.
52. Tuttle KR, Anderson PW (2003) A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 42: 456-465.
53. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, et al. (2006) Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47: 86-92.
54. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, et al. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factorkappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275: 25781-25790.
55. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, et al. (2004) Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 109: 1497-1502.
56. Willfort-Ehringer A, Ahmadi R, Gessl A, Gschwandtner ME, Haumer A, et al. (2004) Neointimal proliferation within carotid stents is more pronounced in diabetic patients with initial poor glycaemic state. Diabetologia 47: 400-406.
57. Torres CR, Hart GW (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 259: 3308-3317.